About this trial
Toxoplasma gondii infects over one third of the global human population. Cerebral toxoplasmosis is the most common opportunistic infection in HIV patients resulting in up to 50% of mortality with proper treatment and 80% without it. The fatality mainly due to the brain edema resulted from the mass effect lesion. In addition of anti toxoplasmosis given, adjunctive therapy such as steroid is recommended in order to reduce brain edema, but the dose and duration of administration in cerebral toxoplasmosis has not been evaluated in a clinical trial. Adjunctive therapy given in cerebral toxoplasmosis patients still remains unclear. Moreover, its safety in immunodeficiency cases is still debatable.
Eligibility criteria
Qualifiers
Age 18 years or above.
Clinical signs and symptoms compatible to cerebral toxoplasmosis
Serology HIV positive
Immunoglobulin G anti-toxoplasma titre is positive
Disqualifiers
History of anti-toxoplasmosis administrattion for more than 5 days before recruitment
Hypersensitivity or other contraindication to dexamethasone
Pregnancy
Trial design
Treatments tested in this trial
- Dexamethasone
- Placebo